PSMAddition is an international, open-label, prospective, phase 3 randomized controlled trial of 177Lu-PSMA-617 plus ADT and ARPI in PSMA-positive mHSPC.
A team of cancer biologists led by Princeton’s Yibin Kang has resolved a confounding paradox about retinoids and cancer cells ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback